OrienX010, another HSV-1-derived OV which expresses GM-CSF, was tested in advanced melanoma, and recent results were published, highlighting the efficacy and safety of the therapy in resectable stage IIIb-IV (M1a) acral melanoma in a phase IB clinical trial (NCT04197882). The gene discussed is CSF2; the disease is melanoma.